Jason Bednar
Stock Analyst at Piper Sandler
(2.21)
# 2,824
Out of 5,124 analysts
191
Total ratings
41.38%
Success rate
-3.62%
Average return
Main Sectors:
Stocks Rated by Jason Bednar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COO The Cooper Companies | Reiterates: Overweight | $83 → $94 | $84.32 | +11.48% | 15 | Dec 5, 2025 | |
| BDX Becton, Dickinson and Company | Maintains: Neutral | $200 → $190 | $205.36 | -7.48% | 11 | Nov 7, 2025 | |
| ICUI ICU Medical | Maintains: Overweight | $153 → $172 | $150.68 | +14.15% | 3 | Nov 7, 2025 | |
| SOLV Solventum | Maintains: Overweight | $94 → $98 | $83.16 | +17.85% | 8 | Nov 7, 2025 | |
| SHC Sotera Health Company | Maintains: Neutral | $15 → $17 | $18.73 | -9.24% | 3 | Nov 5, 2025 | |
| MMSI Merit Medical Systems | Reiterates: Overweight | $105 → $109 | $93.04 | +17.15% | 14 | Oct 31, 2025 | |
| ALGN Align Technology | Reiterates: Overweight | $190 → $200 | $167.66 | +19.29% | 32 | Oct 30, 2025 | |
| KRMD KORU Medical Systems | Maintains: Neutral | $3.5 → $4 | $5.58 | -28.32% | 8 | Aug 7, 2025 | |
| MASI Masimo | Maintains: Overweight | $200 → $210 | $136.60 | +53.73% | 16 | Aug 6, 2025 | |
| NVST Envista Holdings | Maintains: Neutral | $17 → $19 | $23.21 | -18.14% | 13 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $9 → $2.5 | $2.33 | +7.30% | 12 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $34 | $14.29 | +137.93% | 11 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $16 | $12.37 | +29.35% | 8 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $83 → $77 | $78.55 | -1.97% | 7 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4.5 | $3.77 | +19.36% | 3 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $260 → $265 | $260.03 | +1.91% | 9 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $6 | $3.21 | +86.92% | 5 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $5.84 | +19.86% | 5 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $20 | $0.79 | +2,431.65% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $310 → $372 | $592.85 | -37.25% | 4 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $95 | $86.73 | +9.54% | 1 | Apr 19, 2023 |
The Cooper Companies
Dec 5, 2025
Reiterates: Overweight
Price Target: $83 → $94
Current: $84.32
Upside: +11.48%
Becton, Dickinson and Company
Nov 7, 2025
Maintains: Neutral
Price Target: $200 → $190
Current: $205.36
Upside: -7.48%
ICU Medical
Nov 7, 2025
Maintains: Overweight
Price Target: $153 → $172
Current: $150.68
Upside: +14.15%
Solventum
Nov 7, 2025
Maintains: Overweight
Price Target: $94 → $98
Current: $83.16
Upside: +17.85%
Sotera Health Company
Nov 5, 2025
Maintains: Neutral
Price Target: $15 → $17
Current: $18.73
Upside: -9.24%
Merit Medical Systems
Oct 31, 2025
Reiterates: Overweight
Price Target: $105 → $109
Current: $93.04
Upside: +17.15%
Align Technology
Oct 30, 2025
Reiterates: Overweight
Price Target: $190 → $200
Current: $167.66
Upside: +19.29%
KORU Medical Systems
Aug 7, 2025
Maintains: Neutral
Price Target: $3.5 → $4
Current: $5.58
Upside: -28.32%
Masimo
Aug 6, 2025
Maintains: Overweight
Price Target: $200 → $210
Current: $136.60
Upside: +53.73%
Envista Holdings
Aug 1, 2025
Maintains: Neutral
Price Target: $17 → $19
Current: $23.21
Upside: -18.14%
Jul 31, 2025
Downgrades: Neutral
Price Target: $9 → $2.5
Current: $2.33
Upside: +7.30%
Jun 27, 2025
Reiterates: Overweight
Price Target: $34
Current: $14.29
Upside: +137.93%
Apr 30, 2025
Maintains: Neutral
Price Target: $20 → $16
Current: $12.37
Upside: +29.35%
Apr 30, 2025
Maintains: Overweight
Price Target: $83 → $77
Current: $78.55
Upside: -1.97%
Mar 28, 2025
Maintains: Overweight
Price Target: $5 → $4.5
Current: $3.77
Upside: +19.36%
Feb 3, 2025
Maintains: Overweight
Price Target: $260 → $265
Current: $260.03
Upside: +1.91%
Nov 7, 2024
Maintains: Overweight
Price Target: $8 → $6
Current: $3.21
Upside: +86.92%
Aug 15, 2024
Reiterates: Overweight
Price Target: $7
Current: $5.84
Upside: +19.86%
Aug 7, 2024
Maintains: Overweight
Price Target: $70 → $20
Current: $0.79
Upside: +2,431.65%
Jan 3, 2024
Maintains: Outperform
Price Target: $310 → $372
Current: $592.85
Upside: -37.25%
Apr 19, 2023
Initiates: Overweight
Price Target: $95
Current: $86.73
Upside: +9.54%